COSMOS Pharmaceutical Corporation (3349) Price & Analysis

Compare

1 Followers

3349 Stock Chart & Stats

¥7643.00

¥109.00(1.60%)

At close: Jan 08 4:00 PM EST

¥7643.00

¥109.00(1.60%)

Day’s Range― - ―

52-Week Range¥6,544.00 - ¥10,045.00

Previous CloseN/A

Volume659.40K

Average Volume (3M)399.89K

Market Cap

¥600.02B

Enterprise Value¥594.30B

Total Cash (Recent Filing)¥57.04B

Total Debt (Recent Filing)¥49.96B

Price to Earnings (P/E)19.1

Beta-0.28

Next Earnings

Jul 10, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend Yield0.93%

Share Statistics

EPS (TTM)103.10

Shares Outstanding80,001,600

10 Day Avg. Volume586,980

30 Day Avg. Volume399,893

Financial Highlights & Ratios

PEG Ratio0.85

Price to Book (P/B)2.72

Price to Sales (P/S)0.69

P/FCF Ratio-814.90

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

¥9,500.00

Price Target Upside24.30% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering1

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Consistent Revenue GrowthConsistent top-line expansion signals durable demand for OTC and prescription products, supporting scale advantages and R&D funding. Over 2-6 months, steady revenue growth underpins market position, helps absorb fixed costs, and supports reinvestment without relying on volatile financing.

Stable Margins And EfficiencyStable gross and net margins indicate effective cost control across manufacturing and distribution, sustaining profitability despite pricing or input cost cycles. This margin resilience supports long-term cash generation potential and provides flexibility to defend market share in OTC channels.

Solid Balance Sheet And ROELow leverage, a strong equity ratio, and robust ROE provide financial flexibility to fund R&D, strategic investments or weather sector shocks. A healthy balance sheet reduces refinancing risk and supports disciplined capital allocation over the medium term.

Bears Say

Negative Free Cash Flow TrendPersistent negative free cash flow means reported earnings are not fully converting to cash, pressuring liquidity and increasing dependence on external financing or asset sales. Over months this can limit capex, R&D investment, or dividend capacity if not corrected.

Rising Total DebtAn increase in total debt, while currently manageable, raises leverage risk if revenue or margins weaken. Higher debt can constrain strategic options, elevate interest costs, and reduce financial resilience over the medium term, especially if cash conversion remains weak.

Slight Decline In EBIT MarginA recent dip in EBIT margin signals emerging cost pressures or adverse product mix shifts. If persistent, margin erosion would reduce operating cash flow, limit reinvestment capacity, and pressure competitiveness in the OTC market without sustained cost or pricing actions.

COSMOS Pharmaceutical Corporation News

COSMOS Pharmaceutical Overhauls Organization, Launches Legal and Hotel Departments

The latest announcement is out from COSMOS Pharmaceutical Corporation ( ($JP:3349) ). COSMOS Pharmaceutical Corporation has announced a...

1M ago

3349

COSMOS Pharmaceutical Posts Steady First-Half Growth and Confirms Full-Year Outlook

COSMOS Pharmaceutical Corporation ( ($JP:3349) ) has issued an announcement. COSMOS Pharmaceutical reported consolidated net sales of ¥537.2...

1M ago

3349

Upgraded to Buy: COSMOS Pharmaceutical’s Attractive Valuation and Growth Potential

In a report released on December 14, Sho Kawano from Goldman Sachs upgraded COSMOS Pharmaceutical Corporation to a...

2M ago

COSMOS Pharmaceutical Reports Modest Growth in Q3 2025 Financial Results

COSMOS Pharmaceutical Corporation ( ($JP:3349) ) has provided an announcement. COSMOS Pharmaceutical Corporation reported its consolidated financial results...

4M ago

3349

COSMOS Pharmaceutical Considers Lowering Investment Unit to Boost Market Activity

COSMOS Pharmaceutical Corporation ( ($JP:3349) ) has shared an update. COSMOS Pharmaceutical Corporation is considering lowering its investment...

6M ago

3349

COSMOS Pharmaceutical Announces Board of Directors Changes

COSMOS Pharmaceutical Corporation ( ($JP:3349) ) has issued an update. COSMOS Pharmaceutical Corporation has announced changes in its...

7M ago

3349

COSMOS Pharmaceutical Increases Year-End Dividend Following Stock Split

An announcement from COSMOS Pharmaceutical Corporation ( ($JP:3349) ) is now available. COSMOS Pharmaceutical Corporation announced an increase...

7M ago

3349

COSMOS Pharmaceutical Reports Strong Financial Growth for Fiscal Year 2025

COSMOS Pharmaceutical Corporation ( ($JP:3349) ) has provided an announcement. COSMOS Pharmaceutical Corporation reported a significant increase in...

7M ago

3349

COSMOS Pharmaceutical Reports Strong Financial Growth for Nine-Month Period

The latest announcement is out from COSMOS Pharmaceutical Corporation ( ($JP:3349) ). COSMOS Pharmaceutical Corporation reported a significant...

10M ago

3349

COSMOS Pharmaceutical Reports Strong Growth and Strategic Stock Split

The latest announcement is out from COSMOS Pharmaceutical Corporation ( ($JP:3349) ). COSMOS Pharmaceutical Corporation reported strong financial...

1y ago

3349

3349 FAQ

What was COSMOS Pharmaceutical Corporation’s price range in the past 12 months?

COSMOS Pharmaceutical Corporation lowest stock price was ¥6544.00 and its highest was ¥10045.00 in the past 12 months.

What is COSMOS Pharmaceutical Corporation’s market cap?

COSMOS Pharmaceutical Corporation’s market cap is ¥600.02B.

When is COSMOS Pharmaceutical Corporation’s upcoming earnings report date?

COSMOS Pharmaceutical Corporation’s upcoming earnings report date is Jul 10, 2026 which is in 143 days.

How were COSMOS Pharmaceutical Corporation’s earnings last quarter?

COSMOS Pharmaceutical Corporation released its earnings results on Oct 08, 2025. The company reported ¥103.1 earnings per share for the quarter, missing the consensus estimate of ¥112.021 by -¥8.921.

Is COSMOS Pharmaceutical Corporation overvalued?

According to Wall Street analysts COSMOS Pharmaceutical Corporation’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does COSMOS Pharmaceutical Corporation pay dividends?

COSMOS Pharmaceutical Corporation pays a Semiannually dividend of ¥37.5 which represents an annual dividend yield of 0.93%. See more information on COSMOS Pharmaceutical Corporation dividends here

What is COSMOS Pharmaceutical Corporation’s EPS estimate?

COSMOS Pharmaceutical Corporation’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does COSMOS Pharmaceutical Corporation have?

COSMOS Pharmaceutical Corporation has 80,001,600 shares outstanding.

What happened to COSMOS Pharmaceutical Corporation’s price movement after its last earnings report?

COSMOS Pharmaceutical Corporation reported an EPS of ¥103.1 in its last earnings report, missing expectations of ¥112.021. Following the earnings report the stock price went up 0.925%.

Which hedge fund is a major shareholder of COSMOS Pharmaceutical Corporation?

Currently, no hedge funds are holding shares in JP:3349

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

COSMOS Pharmaceutical Corporation

COSMOS Pharmaceutical Corporation (3349) is a prominent player in the Japanese pharmaceutical industry, specializing in the manufacture and distribution of a wide range of healthcare products. The company operates primarily in the over-the-counter (OTC) drug sector, providing consumers with accessible health solutions that include pain relievers, cold remedies, and dietary supplements. In addition to OTC medications, COSMOS also engages in the development of prescription drugs and health-related products, aiming to enhance the quality of life for its customers.

COSMOS Pharmaceutical Corporation (3349) Earnings & Revenues

Historic Earnings Reports

3349 Stock 12 Month Forecast

Average Price Target

¥9,500.00

▲(24.30% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"6635":"¥6,635","8068":"¥8,068","9501":"¥9,501","7351.5":"¥7,351.5","8784.5":"¥8,784.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":9500,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">¥10K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":9500,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">¥10K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":9500,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">¥10K</span>\n  </div></div>","useHTML":true}}],"tickPositions":[6635,7351.5,8068,8784.5,9501],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2025","6":"May<br/>2025","9":"Aug<br/>2025","12":"Jan<br/>2026","25":"Jan<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,7943,8062.7692307692305,8182.538461538462,8302.307692307691,8422.076923076924,8541.846153846154,8661.615384615385,8781.384615384615,8901.153846153846,9020.923076923076,9140.692307692309,9260.461538461539,9380.23076923077,{"y":9500,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,7943,8062.7692307692305,8182.538461538462,8302.307692307691,8422.076923076924,8541.846153846154,8661.615384615385,8781.384615384615,8901.153846153846,9020.923076923076,9140.692307692309,9260.461538461539,9380.23076923077,{"y":9500,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,7943,8062.7692307692305,8182.538461538462,8302.307692307691,8422.076923076924,8541.846153846154,8661.615384615385,8781.384615384615,8901.153846153846,9020.923076923076,9140.692307692309,9260.461538461539,9380.23076923077,{"y":9500,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":7248.36,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7028.38,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7374.22,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6636,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6978.85,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7428.72,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9136.02,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8921.49,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9119.5,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9495.63,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8770.24,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8474.72,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 21, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7943,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 38, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >